Scynexis

Contributing Author

Recent Articles by Scynexis

Jan-28	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) SCYX GlobeNewswire
Jan-21	SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 SCYX GlobeNewswire
Dec-22	SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement SCYX GlobeNewswire
Nov-19	SCYNEXIS Completes Transfer of BREXAFEMME New Drug Application to GSK SCYX GlobeNewswire
Nov-17	Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections SCYX GlobeNewswire
Nov-05	SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update SCYX -5.48% SCYX GlobeNewswire
Oct-15	SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study SCYX GlobeNewswire
Sep-30	SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) SCYX -26.67% GlobeNewswire
Sep-04	SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) SCYX GlobeNewswire
Aug-25	SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 - 10, 2025 SCYX GlobeNewswire
Aug-13	SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update SCYX -5.15% SCYX GlobeNewswire
May-28	SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study SCYX +28.04% GlobeNewswire
May-15	SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update SCYX -19.29% SCYX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.